PR Newswire PharmaOriginal article
Cyrano Therapeutics Announces CYR-064 Phase 2 FLAVOR Trial Results to be Featured at the 72nd Annual Meeting of the American Rhinologic Society
Data ReadoutCYR-064Positive
AI Analysis
Summary
Cyrano Therapeutics announced that Phase 2 FLAVOR trial results for CYR-064, evaluating treatment for persistent post-viral loss of smell, will be presented at the American Rhinologic Society's annual meeting.
Clinical Trial Data
Phase
2
Outcome Details
Phase 2 FLAVOR trial results to be presented at 72nd Annual Meeting of the American Rhinologic Society
Importance:5/10
Sentiment:
0.50
Phase 2clinical datasmell disordersconference presentationregenerative medicine
Read the original article
Published by PR Newswire Pharma on July 29, 2026 12:10 PM